Karolinska Development Gestion

Gestion contrôle des critères 3/4

Le PDG Karolinska Development est Viktor Drvota, nommé en Jun2017, a un mandat de 7.42 ans. La rémunération annuelle totale est SEK 4.73M, composée du salaire de 62.9% et des bonus 37.1%, y compris les actions et options de la société. détient directement 0.078% des actions de la société, d'une valeur de € 19.28K. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 4.5 ans et 2.8 ans.

Informations clés

Viktor Drvota

Directeur général

SEK 4.7m

Rémunération totale

Pourcentage du salaire du PDG	62.9%
Durée du mandat du directeur général	7.4yrs
Propriété du PDG	0.08%
Durée moyenne d'occupation des postes de direction	4.5yrs
Durée moyenne du mandat des membres du conseil d'administration	2.8yrs

Mises à jour récentes de la gestion

Recent updates

Analyse de la rémunération des PDG

Comment la rémunération de Viktor Drvota a-t-elle évolué par rapport aux bénéfices de Karolinska Development?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Sep 30 2024	n/a	n/a	-SEK 29m
Jun 30 2024	n/a	n/a	-SEK 6m
Mar 31 2024	n/a	n/a	SEK 34m
Dec 31 2023	SEK 5m	SEK 3m	SEK 5m
Sep 30 2023	n/a	n/a	SEK 17m
Jun 30 2023	n/a	n/a	-SEK 41m
Mar 31 2023	n/a	n/a	-SEK 87m
Dec 31 2022	SEK 6m	SEK 3m	-SEK 88m
Sep 30 2022	n/a	n/a	-SEK 118m
Jun 30 2022	n/a	n/a	-SEK 72m
Mar 31 2022	n/a	n/a	SEK 166m
Dec 31 2021	SEK 5m	SEK 3m	SEK 171m
Sep 30 2021	n/a	n/a	SEK 276m
Jun 30 2021	n/a	n/a	SEK 108m
Mar 31 2021	n/a	n/a	-SEK 106m
Dec 31 2020	SEK 5m	SEK 3m	-SEK 207m
Sep 30 2020	n/a	n/a	SEK 35m
Jun 30 2020	n/a	n/a	SEK 190m
Mar 31 2020	n/a	n/a	SEK 195m
Dec 31 2019	SEK 6m	SEK 3m	SEK 303m
Sep 30 2019	n/a	n/a	-SEK 11m
Jun 30 2019	n/a	n/a	SEK 8m
Mar 31 2019	n/a	n/a	SEK 32m
Dec 31 2018	SEK 5m	SEK 3m	SEK 31m
Sep 30 2018	n/a	n/a	SEK 48m
Jun 30 2018	n/a	n/a	SEK 238m
Mar 31 2018	n/a	n/a	SEK 185m
Dec 31 2017	SEK 5m	SEK 1m	SEK 180m

Rémunération vs marché: La rémunération totale de Viktor ($USD 430.34K ) est dans la moyenne des entreprises de taille similaire sur le marché German ($USD 474.54K ).

Rémunération et revenus: La rémunération de Viktor a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.

PDG

Viktor Drvota (59 yo)

7.4yrs

Titularisation

SEK 4,733,000

Compensation

Dr. Viktor Drvota, M.D., Ph D., has been an Independent Director of OssDsign AB since 2015. He serves as Chairman of the Board at Modus Therapeutics Holding Ab since 2016.He serves as the Chief Executive...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Viktor Drvota	Chief Executive Officer	7.4yrs	SEK 4.73m	0.078% € 19.3k
Hans Toll	Chief Financial Officer	2.1yrs	pas de données	0.013% € 3.2k
Per Aniansson	Investment Director	3.7yrs	pas de données	0.059% € 14.7k
Eva Montgomerie	Head of Accounting	11.1yrs	pas de données	0.012% € 3.0k
John Öhd	Chief Scientific Officer & Venture Partner	4.4yrs	pas de données	pas de données
Johan Dighed	Chief Legal Officer & Deputy CEO	4.5yrs	pas de données	0.15% € 36.7k
Yan Cheng	President of Asia	7.3yrs	pas de données	0.0093% € 2.3k
Tse Ping	Senior Strategic Advisor	no data	pas de données	pas de données
Linda Spahiu	Investment Manager	no data	pas de données	0.0037% € 919.2
Mikaela Sörman	Investment Manager	no data	pas de données	0.0037% € 919.2

4.5yrs

Durée moyenne de l'emploi

54.5yo

Âge moyen

Gestion expérimentée: L'équipe de direction de 2I9 est considérée comme expérimentée (ancienneté moyenne 4.5 ans).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Hans Wigzell	Chairman	less than a year	SEK 500.00k	pas de données
Anna Lefevre Skjoldebrand	Independent Director	3.8yrs	SEK 200.00k	pas de données
Ben Toogood	Director	3.8yrs	SEK 178.00k	0.024% € 5.9k
Will Zeng	Director	no data	pas de données	pas de données
Philip Duong	Director	2.8yrs	SEK 200.00k	pas de données

2.8yrs

Durée moyenne de l'emploi

51.5yo

Âge moyen

Conseil d'administration expérimenté: Le conseil d'administration de la 2I9 n'est pas considéré comme expérimenté ( 2.8 années d'ancienneté moyenne), ce qui suggère un nouveau conseil d'administration.

Karolinska Development Gestion

Gestion contrôle des critères 3/4

Informations clés

Mises à jour récentes de la gestion

Karolinska Development AB Announces CEO Changes to its Portfolio Company SVF Vaccines

Karolinska Development AB (Publ) Announces That Björn Cochlovius Has Declined Re-Election

Chief Executive Officer recently bought €7.2k worth of stock

Karolinska Development AB (publ), Annual General Meeting, May 16, 2023

Less than half of directors are independent

Karolinska Development AB Announces Chief Financial Officer Changes

Recent updates

Third quarter 2024 earnings released: kr0.04 loss per share (vs kr0.044 profit in 3Q 2023)

Karolinska Development AB Announces CEO Changes to its Portfolio Company SVF Vaccines

An undisclosed buyer acquired 15% stake in Henlez ApS from Karolinska Development AB (publ) (OM:KDEV).

Second quarter 2024 earnings released: kr0.059 loss per share (vs kr0.086 profit in 2Q 2023)

Karolinska Development AB (publ) to Report Fiscal Year 2024 Final Results on Mar 21, 2025

New major risk - Share price stability

First quarter 2024 earnings released

Karolinska Development AB (Publ) Announces That Björn Cochlovius Has Declined Re-Election

Full year 2023 earnings released: EPS: kr0.02 (vs kr0.34 loss in FY 2022)

New major risk - Revenue and earnings growth

Chief Executive Officer recently bought €7.2k worth of stock

Full year 2023 earnings released: EPS: kr0.02 (vs kr0.34 loss in FY 2022)

Karolinska Development AB (publ) to Report First Half, 2024 Results on Aug 30, 2024

New major risk - Revenue and earnings growth

Karolinska Development AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 40.3 million.

Ossdsign Receives FDA Clearance for the Use of OssDsign Catalyst in Interbody Cages in Spinal Surgery

Second quarter 2023 earnings released: EPS: kr0.086 (vs kr0.083 loss in 2Q 2022)

Full year 2022 earnings released: kr0.34 loss per share (vs kr0.97 profit in FY 2021)

Full year 2022 earnings released: kr3.43 loss per share (vs kr0.97 profit in FY 2021)

Karolinska Development AB (Publ) Announces That Its Portfolio Company Dilafor’S Extended Clinical Phase 2B Study with the Drug Candidate Tafoxiparin Has Resulted in Further Positive Data

Third quarter 2022 earnings released

Karolinska Development AB (publ) to Report First Half, 2023 Results on Aug 25, 2023

Karolinska Development AB (publ), Annual General Meeting, May 16, 2023

Less than half of directors are independent

Modus Therapeutics AB's Portfolio Company Modus Therapeutics Completes Recruitment in a Clinical Phase 1B Study of Sevuparin

Karolinska Development AB Announces Chief Financial Officer Changes

Karolinska Development’s portfolio company Modus Therapeutics initiates inclusion in phase 1 study of sevuparin in pediatric patients with severe malaria

Second quarter 2022 earnings released

Karolinska Development's Portfolio Company Initiated A Clinical Phase 1 Program with PN-6047

Karolinska Development AB (publ) to Report Fiscal Year 2022 Results on Feb 17, 2023

First quarter 2022 earnings released

Less than half of directors are independent

Karolinska Development AB (Publ) Announces Portfolio Company Ossdsign Completes Patient Enrolment to the Top Fusion Study

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Karolinska Development AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 377.64874 million.

Organon & Co. (NYSE:OGN) completed the acquisition of Forendo Pharma Ltd from Karolinska Development AB (publ) (OM:KDEV), KD Co-Investment Fund KB, fund managed by Karolinska Development AB (publ) and others.

Karolinska Development’s Portfolio Company Modus Therapeutics Initiates Phase 1b Trial of Its Drug Candidate Sevuparin

Third quarter 2021 earnings released

Investor sentiment improved over the past week

Second quarter 2021 earnings released: EPS kr1.23 (vs kr0.012 in 2Q 2020)

Karolinska Development AB Announces the US Food and Drug Administration Issued A Clinical Hold for Aprea Therapeutics Clinical Program

Karolinska Development AB (publ) (OM:KDEV) acquired additional 21% minority stake in Anacardio AB.

First quarter 2021 earnings released

Full year 2020 earnings released: kr1.18 loss per share (vs kr4.10 profit in FY 2019)

CFO & Deputy CEO Fredrik Jarrsten has left the company

Karolinska Development AB Announces CFO Changes

Karolinska Development Appoints Johan Dighed as Deputy CEO

Karolinska Development AB (publ) Announces Management Appointments

Full year 2020 earnings released: kr1.18 loss per share (vs kr4.10 profit in FY 2019)

New 90-day low: €0.21

New 90-day low: €0.23

New 90-day low: €0.23

New 90-day low - €0.23

Karolinska Development AB (publ) (OM:KDEV) acquired 5% stake in Svenska Vaccinfabriken Produktion AB.

Analyse de la rémunération des PDG

PDG

Titularisation

Compensation

Équipe de direction

Durée moyenne de l'emploi

Âge moyen

Membres du conseil d'administration

Durée moyenne de l'emploi

Âge moyen